News

Patient advocates debate whether FDA approval on small, early clinical studies is too fast-tracked for efficacy and safety, or too slow due to long review processes.

Addressing the current hurdles and potential solutions in nonalcoholic steatohepatitis awareness and clinical trial enrollment.

A look at the opportunities and challenges around patient-centric trials and patient centricity in pharma.

The consequences UK faces after being pulled out of the EU without any healthcare and research deal may affect all of Europe.

Navigating the many complexities in clinical trials, manufacturing, and regulatory interaction in moving gene therapies from development to market.

Exploring the use of electronic investigator site files for review of regulatory documents and informed consents.

While obstacles may persist with limited access for patients and researchers, technology can help with this cancer clinical trial paradox.

As pharma businesses shift their focus away from ‘blockbusters’ to treatments for rare diseases, clinical trial design must also go through a period of change and should consider response-adaptive over traditional randomized controlled trial designs.

The possibility of a "no-deal" Brexit scenario would have severe repercussions for clinical trials not only in the UK, but the rest of Europe as well.

Becky Carpenter, Head of North America/Euro Operations at WuXi Clinical, a newly formed CRO, discusses the evolution of the mid-sized pharma and CRO space-and the level of support now needed for some of the smaller and more nimble customers.